A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
1d
The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...
The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...
Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed.
The Medicare insurance program now pays for drugs like Novo Nordisk A/S’s Ozempic and Eli Lilly & Co.’s Mounjaro for people ...
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback